Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature
Introduction: Glioblastoma is a fatal intracranial neoplasm that is refractory to treatment, with inevitable disease recurrence and progression to death. Marine-derived compounds, including those found in nutraceutical products, may provide therapeutic benefit in the setting of glioblastoma. We pres...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Onco |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-7523/4/4/26 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850035500763578368 |
|---|---|
| author | Nishika Karbhari Simon Khagi |
| author_facet | Nishika Karbhari Simon Khagi |
| author_sort | Nishika Karbhari |
| collection | DOAJ |
| description | Introduction: Glioblastoma is a fatal intracranial neoplasm that is refractory to treatment, with inevitable disease recurrence and progression to death. Marine-derived compounds, including those found in nutraceutical products, may provide therapeutic benefit in the setting of glioblastoma. We present two patient cases whose courses demonstrate a compelling role for marine-derived products in the management of glioblastoma. Cases: Case 1 describes a patient with <i>MGMT</i> promoter unmethylated glioblastoma who went on to complete standard of care chemoradiation along with concurrent use of a majority sea cucumber (MSC) blend known as SeaCare<sup>®</sup> (SeaCare, Torrington, CT, USA). Her survival of over 2 years significantly exceeds the recognized median survival time of glioblastoma. Case 2 describes a patient with a complicated course who experienced dramatic improvement after the initiation of the MSC blend, with an exceptional survival time of over 4 years post-diagnosis. Discussion: The mechanisms of marine-derived products that underlie these dramatic clinical effects are likely multifaceted but may hinge on the modification of the tumor immune microenvironment and suppression of tumorigenic effects. Specifically, the change in tumor-associated macrophages (TAMs) within the tumor microenvironment is central to this complex interplay. Conclusions: Ultimately, the use of marine products in the treatment of glioblastoma may present a novel and promising therapeutic strategy that warrants further investigation. |
| format | Article |
| id | doaj-art-b7b2950d9a2c47f2967a320c01353ad0 |
| institution | DOAJ |
| issn | 2673-7523 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Onco |
| spelling | doaj-art-b7b2950d9a2c47f2967a320c01353ad02025-08-20T02:57:28ZengMDPI AGOnco2673-75232024-11-014436938010.3390/onco4040026Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the LiteratureNishika Karbhari0Simon Khagi1Department of Neurology, Mayo Clinic, Rochester, MN 55905, USAHoag Family Cancer Institute, Newport Beach, CA 92663, USAIntroduction: Glioblastoma is a fatal intracranial neoplasm that is refractory to treatment, with inevitable disease recurrence and progression to death. Marine-derived compounds, including those found in nutraceutical products, may provide therapeutic benefit in the setting of glioblastoma. We present two patient cases whose courses demonstrate a compelling role for marine-derived products in the management of glioblastoma. Cases: Case 1 describes a patient with <i>MGMT</i> promoter unmethylated glioblastoma who went on to complete standard of care chemoradiation along with concurrent use of a majority sea cucumber (MSC) blend known as SeaCare<sup>®</sup> (SeaCare, Torrington, CT, USA). Her survival of over 2 years significantly exceeds the recognized median survival time of glioblastoma. Case 2 describes a patient with a complicated course who experienced dramatic improvement after the initiation of the MSC blend, with an exceptional survival time of over 4 years post-diagnosis. Discussion: The mechanisms of marine-derived products that underlie these dramatic clinical effects are likely multifaceted but may hinge on the modification of the tumor immune microenvironment and suppression of tumorigenic effects. Specifically, the change in tumor-associated macrophages (TAMs) within the tumor microenvironment is central to this complex interplay. Conclusions: Ultimately, the use of marine products in the treatment of glioblastoma may present a novel and promising therapeutic strategy that warrants further investigation.https://www.mdpi.com/2673-7523/4/4/26glioblastomamicroenvironmenttumor-associated macrophagemarine derivedsea cucumberseagrass |
| spellingShingle | Nishika Karbhari Simon Khagi Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature Onco glioblastoma microenvironment tumor-associated macrophage marine derived sea cucumber seagrass |
| title | Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature |
| title_full | Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature |
| title_fullStr | Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature |
| title_full_unstemmed | Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature |
| title_short | Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature |
| title_sort | marine derived therapeutics for the management of glioblastoma a case series and comprehensive review of the literature |
| topic | glioblastoma microenvironment tumor-associated macrophage marine derived sea cucumber seagrass |
| url | https://www.mdpi.com/2673-7523/4/4/26 |
| work_keys_str_mv | AT nishikakarbhari marinederivedtherapeuticsforthemanagementofglioblastomaacaseseriesandcomprehensivereviewoftheliterature AT simonkhagi marinederivedtherapeuticsforthemanagementofglioblastomaacaseseriesandcomprehensivereviewoftheliterature |